Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy (ZLd_Ld)

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by (Responsible Party):
Tiziana Marangon, University of Turin, Italy
ClinicalTrials.gov Identifier:
NCT01501370
First received: December 16, 2011
Last updated: May 9, 2016
Last verified: May 2016
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Study Completion Date: January 2012
  Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)